As these dedifferentiated or progenitor cells have been implicated in both tumorigenesis [5] and therapeutic resistance [6], we sought to determine if nestin expression level could be used as a clinically relevant prognosticator in GBM. The gene discussed is NES; the disease is glioblastoma.